My Blog

Fuad El-Hibri (born March 2, 1958) is an American businessman, and CEO of Emergent BioSolutions. Fuad El-Hibri (born March 2, 1958) in Hildesheim, Germany spent his childhood equally in Europe and the Middle East before coming to the USA to get an economics degree from Stanford and an MBA from Yale.

Mr.El-Hibri earned a Masters Degree in Public and Private Management from Yale University and a Bachelors Degree with Honors in Economics from Stanford University.

Fuad El-Hibri served as president of Digicel from August 2000 to February 2005. Mr. El-Hibri served as the president of East West Resources Corporation from September 1990 to January 2004

Mr. El-Hibri was a member of the senior management team of Speywood, LTD., in the United Kingdom. and organized and directed the management buyout of Porton Products Ltd. El-Hibri reorganized Porton, and was advisor to the senior management team involved in the oversight of operations and served as a senior associate and resident project manager at Booz Allen Hamilton and as a manager of Citicorp in New York (Mergers and Acquisitions), and in Jeddah, Saudi Arabia (Operations and Credit).

Mr. El-Hibri has been chairman of East West Resources Corporation, a venture capital and financial consulting firm, since June 1990. He served as the chairman of Digicel Holdings from August 2000 to October 2006. He serves as director of Emergent BioDefense Operations Lansing Inc.El-Hibri has been Director and CEO of Emergent BioSolutions since 2004 and He serves as Chairman and Treasurer of El-Hibri Charitable Foundation.

Mr.El-Hibri serves as a member of the board of trustees of American University. He is a member of the board of directors of the International Biomedical Research Alliance (an academic joint venture among the National Institutes of Health, Oxford University and Cambridge University). Mr El-Hibri is also a member of the board of trustees of the National Health Museum.

Emergent BioSolutions Chairman and CEO, Mr. Fuad El-Hibri, Named Ernst & Young Entrepreneur of the Year 2009 Award Winner in Greater Washington

ROCKVILLE, MD, June 18, 2009 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that Fuad El-Hibri, its chairman and chief executive officer, received the Ernst & Young Entrepreneur of the Year® 2009 Award in the Technology category in Greater Washington.  According to Ernst & Young LLP, the award recognizes outstanding entrepreneurs who are building and leading dynamic, growing businesses.  Mr. El-Hibri was selected by an independent panel of judges and the award was presented at a special gala event on June 18 at the Ritz-Carlton, Tysons Corner in Virginia.

“It is a tremendous honor to receive this award considering the many biopharmaceutical and life sciences companies in the greater Washington region,” said Mr. El-Hibri.  “I am proud of Emergent BioSolutions’ continuous growth and financial strength.  These successes are firmly anchored on the entrepreneurial spirit and commitment of our employees.  All their contributions, in pursuit of our company mission to protect life, have made this award possible.”

Under Mr. El-Hibri’s leadership, Emergent BioSolutions has expanded its capabilities in the development and manufacture of vaccines and immune-related therapeutics.  By strengthening its core biodefense portfolio, which includes the only FDA-licensed vaccine against anthrax disease, Emergent has become the premier biodefense supplier of medical countermeasures to the U.S. government.

The Ernst & Young Entrepreneur of the Year awards program celebrates its 23rd anniversary this year and continues to honor entrepreneurs who have demonstrated excellence in such areas as innovation, financial performance, and personal commitment to their businesses and communities.  The program has expanded to recognize business leaders in over 135 cities in 50 countries throughout the world.

As a Greater Washington award winner, Mr. El-Hibri is now eligible for consideration for the Ernst & Young Entrepreneur of the Year 2009 national program.  Award winners in several national categories, as well as the overall national Ernst & Young Entrepreneur of the Year award winner, will be announced at the annual awards gala in Palm Springs, California on November 14, 2009.  The awards are the culminating event of the Ernst & Young Strategic Growth Forum, the nation’s most prestigious gathering of high-growth, market-leading companies.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body’s immune system to prevent or treat disease.  Emergent’s marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine licensed by the U.S. Food and Drug Administration for the prevention of anthrax.  Emergent’s development pipeline includes programs focused on anthrax, botulism, tuberculosis, typhoid, hepatitis B and chlamydia.  Additional information may be found at www.emergentbiosolutions.com.

About Ernst & Young’s Entrepreneur of the Year® Awards Program

Ernst & Young’s Entrepreneur of the Year® Award is the world’s most prestigious business award for entrepreneurs. The award makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, the Ernst & Young Entrepreneur of the Year® award celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 135 cities in 50 countries.

Sponsors

Founded and produced by Ernst & Young LLP, the Entrepreneur of the Year awards are pleased to have the Ewing Marion Kauffman Foundation and SAP America as national sponsors.

In Greater Washington, sponsors include HSBC Bank, Pillsbury Law, Reznick Group, Lockton Companies and the Washington Business Journal.

###

Miko B. Neri
Senior Manager
Corporate Communications
Emergent BioSolutions
2273 Research Boulevard, Suite 400
Rockville, Maryland 20850
t  301 795 1859
f  301 795 1850
c  240 938 6296
e  nerim@ebsi.com
www.emergentbiosolutions.com